NewAmsterdam Pharma (NAMS) Total Non-Current Liabilities (2021 - 2026)

NewAmsterdam Pharma has reported Total Non-Current Liabilities for 6 years, with the latest figure at $17.2 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 1.91% year-over-year to $17.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.2 million (down 1.91% YoY) and the FY2025 annual result came in at $28.6 million, up 15.21% from the prior year.
• Total Non-Current Liabilities retreated to $17.2 million in Q1 2026 per NAMS's latest filing, from $28.6 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $60.2 million in Q1 2024 and troughed at $11432.6 in Q2 2023.
• A 5-year average of $27.3 million and a median of $21.2 million in 2024 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities surged 401006.76% in 2024, then plunged 70.87% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $11.8 million in 2022, then surged by 330.18% to $50.9 million in 2023, then tumbled by 51.28% to $24.8 million in 2024, then rose by 15.21% to $28.6 million in 2025, then slumped by 39.85% to $17.2 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $17.2 million, $28.6 million, and $14.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.